The 5-HT1A receptor full agonist, 8-OH-DPAT inhibits ACTH-induced 5-HT2A receptor hyperfunction in rats: Involvement of 5-HT1A receptors in the DOI-induced wet-dog shakes in ACTH-treated rats

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 1, 2007, Pages 117-120

  Kitamura, Yoshihisa ^a,b   Kitagawa, Kouhei ^b   Fujitani, Yoshika ^b   Shibata, Kazuhiko ^b   Araki, Hiroaki ^c   Sendou, Toshiaki ^b   Gomita, Yutaka ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

( ) 1 (2,5 dimethoxy 4 iodophenyl) 2 aminopropane (DOI); 5 HT1Areceptor; 5 HT2Areceptor; 8 hydroxy 2 di n propylamino tetralin (8 OH DPAT); Wet dog shake

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; KETANSERIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; TETRACOSACTIDE ZINC PHOSPHATE; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; AMPHETAMINE DERIVATIVE; CORTICOTROPIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY POSTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INHIBITION; DRUG MECHANISM; HYPOTHERMIA; MALE; NONHUMAN; PROTEIN FUNCTION; RAT; WET DOG SHAKES; ANIMAL; BODY TEMPERATURE; BRAIN; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; TIME; TREMOR; WISTAR RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADRENOCORTICOTROPIC HORMONE; AMPHETAMINES; ANIMALS; BODY TEMPERATURE; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOTHERMIA; KETANSERIN; MALE; POSTURE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TIME FACTORS; TREMOR;

EID: 33846119311     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.117     Document Type: Article

References (18)

1. Peroutka S. J., Annu. Rev. Neurosci., 11, 45-60 (1988).
2. Cowen P. J., Br. J. Psychiatry, 159 (Suppl. 12), 7-14 (1991).
3. Mann J. I., Stanley M., McBride P. A., McEwen B. S., Arch. Gen. Psychiatry, 43, 954-959 (1986).
4. Arora R. C., Meltzer H. Y., Am. J. Psychiatry, 146, 730-736 (1989).
5. Arango V., Ernsberger P., Marzuk P. M., Chen J-S., Tierney H., Stanley M., Reis D. J., Mann J. J., Arch. Gen. Psychiatry, 47, 1038-1047 (1990).
6. Kitamura Y., Araki H., Suemaru K., Gomita Y., Pharmacol. Biochem. Behav., 72, 397-402 (2002).
7. Mendelson S. D., McEwen B. S., Neuroendocrinology, 55, 444-450 (1992).
8. Czyrak A., Mackowiak M., Chocyk A., Fijal K., Tokarski K., Bijak M., Wedzony K., Naunyn-Schmiedeberg's Arch. Pharmacol., 366, 357-367 (2002).
9. Takao K., Nagatani T., Kitamura Y., Yamawaki S., Eur. J. Pharmacol., 333, 123-128 (1997).
10. Arnt J., Hyttel J., Eur. J. Pharmacol., 161, 45-51 (1989).
11. Berendsen H. H. G., Broekkamp C. L. E., Br. J. Pharamacol., 101, 667-673 (1990).
12. Darmani N. A., Martin B. R., Pandey U., Glennon R. A., Pharmacol. Biochem. Behav., 36, 901-906 (1990).
13. Dursun S. M., Handley S. L., Br. J. Pharamacol., 109, 1046-1052 (1993).
14. Amsterdam J. D., Berwish N., Potter L., Rickels K., Curr. Ther. Res., 41, 185-193 (1987).
15. LePoul E., Laaris N., Doucet E., Laporte A-M., Hamon M., Lanfumey L., Naunyn-Schmiedeberg's Arch. Pharmacol., 352, 141-148 (1995).
16. Wieland S., Fischette C. T., Lucki I., Neuropharmacology, 32, 561-573 (1993).
17. Bedard P., Pycock C. J., Neuropharmacology, 16, 663-670 (1977).
18. Tricklebank M. D., Forler C., Fozard J. R., Eur. J. Pharmacol., 106, 271-282 (1984).